Loading stock data…
$7.63-0.07 (-0.85%)
Kamada Ltd.
Kamada Ltd. in the Healthcare sector is trading at $7.62 with a market capitalization of $463M. Wall Street consensus targets $13.50 (4 analysts), implying a +77.0% move over the next 12 months. The stock is currently 18% below its 52-week high of $9.35, remaining 2.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $54.92M↑ | $45.24M↑ | $44.68M↓ | $47.01M↑ | $44.75M |
| Gross Profit | $22.47M↑ | $19.12M↑ | $16.97M↓ | $19.76M↑ | $18.93M |
| Operating Income | $9.51M↑ | $6.95M↑ | $3.55M↓ | $7.82M↑ | $7.07M |
| Net Income | $9.26M↑ | $4.13M↑ | $3.56M↓ | $5.30M↓ | $7.38M |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung ...